Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults.: HP5-148/2022E-PDF
"On November 3, 2022, Health Canada authorized the use of the Moderna Spikevax 50 mcg BA.4/5 bivalent COVID-19 vaccine as a booster dose in individuals 18 years of age and older"--Overview, page 3.
Permanent link to this Catalogue record:
publications.gc.ca/pub?id=9.916714&sl=0
| Department/Agency |
|
|---|---|
| Title | Summary of National Advisory Committee on Immunization (NACI) updates of November 3, 2022 : recommendations on the use of Moderna Spikevax BA.4/5 bivalent mRNA (50 mcg) COVID-19 booster vaccine in adults. |
| Variant title |
|
| Publication type | Monograph |
| Language | [English] |
| Other language editions | [French] |
| Format | Digital text |
| Electronic document | |
| Note(s) |
|
| Publishing information |
|
| Description | 1 online resource (3 pages) |
| ISBN | 9780660460291 |
| Catalogue number |
|
| Departmental catalogue number | 220546 |
| Subject terms |
Request alternate formats
To request an alternate format of a publication, complete the Government of Canada Publications email form. Use the form’s “question or comment” field to specify the requested publication.Page details
- Date modified: